Ying Yiu

Abstract Over the last decade, more data has revealed that increased surface expression of the "don't eat me" CD47 protein on cancer cells plays a role in immune evasion and tumor progression, with CD47 blockade emerging as a new therapy in immuno-oncology. CD47 is critical in regulating cell homeostasis and clearance, as binding of CD47 to the inhibitory receptor SIRPα can prevent phagocytosis and macrophage-mediated cell clearance.

This work was supported by funds from the Virginia and D.K. Ludwig Fund for Cancer Research, the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. M.C.T. and Y.Y.Y. were supported by a Stanford Immunology Training Grant (National Institutes of Health Grant 5T32AI007290).

Open Access Ying Ying Yiu, Paige S. Hansen, Laughing Bear Torrez Dulgeroff, Grace Blacker, Lara Myers, Sarah Galloway, Eric Gars, Olivia Colace, Paul Mansfield, Kim J. Hasenkrug, Irving L. Weissman and Michal Caspi Tal J Immunol March 2, 2022, ji2100352; DOI: https://doi.org/10.4049/jimmunol.2100352 Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.